Aurobindo Pharma Receives USFDA Approval for Two Oral Suspension Products
2 hours agoBusiness
39LENS
2 Sources
TBNthebalanced.news

Aurobindo Pharma Receives USFDA Approval for Two Oral Suspension Products

Aurobindo Pharma has received USFDA approval for its Dextromethorphan Polistirex extended-release oral suspension, 30 mg 5 mL (OTC), used to relieve cough caused by minor throat and bronchial irritation. The product, bioequivalent to RB Health's Delsym, will be manufactured at Aurobindo's Unit IV and is expected to launch in Q2 FY27. Additionally, the company obtained approval for Glycerol Phenylbutyrate Oral Liquid, to be produced at Unit III with an immediate market launch planned.

Political Bias
0%100%0%
Sentiment
75%
AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 20 Apr 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 2 sources
● Left 0%● Center 100%● Right 0%

The articles focus on corporate and regulatory developments without political framing. Coverage centers on Aurobindo Pharma's product approvals by the USFDA, presenting information from company announcements and market data. There is no evident political perspective or partisan interpretation, reflecting a neutral business and regulatory viewpoint.

Sentiment — Positive (75/100)

The tone across the articles is generally positive, highlighting regulatory approvals and upcoming product launches as favorable developments for Aurobindo Pharma. The coverage emphasizes growth prospects and market potential without critical or negative commentary, maintaining an optimistic but factual sentiment.

How 2 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
businessstandardAurobindo Pharma gets USFDA nod for Dextromethorphan Oral SuspensionCenterPositive
moneycontrolAurobindo Pharma shares in focus on USFDA approval for cough syrup- Moneycontrol.comCenterPositive

Coverage timeline

moneycontrol broke this story on 20 Apr, 02:11 am. Other outlets followed.

  1. 1
    moneycontrol20 Apr, 02:11 am
    Aurobindo Pharma shares in focus on USFDA approval for cough syrup- Moneycontrol.com
  2. 2
    businessstandard20 Apr, 05:10 am
    Aurobindo Pharma gets USFDA nod for Dextromethorphan Oral Suspension

Lens Score breakdown

39/100
Public interest0/100
Coverage gap100%

Story is receiving appropriate media attention relative to public interest.

Who's involved

Institutions and figures named across source coverage.

Government
U.S. Food and Drug Administration
Corporate
Krishival FoodsAAVAS FinanciersAurobindo PharmaRB Health (US) LLCAPL HealthcareHDFC BankSterling and Wilson RenewableHorizon Therapeutics U.S. Holding LLC

Story context

Category
Business
Sources analysed
2
Last analysed
20 Apr 2026
Key entities
DextromethorphanAurobindo PharmaFood and Drug AdministrationSuspension (chemistry)CoughIrritationCommon coldOver-the-counter drugBronchusBioequivalenceAbbreviated New Drug ApplicationSubsidiary